{"classes":[{"categories":[{"measurements":[{"comment":"There were no responders in this group so that means they did not have a mean percentage of E6 TCR cells at one month.","groupId":"OG000","value":"NA"},{"comment":"There were no responders in this group so that means they did not have a mean percentage of E6 TCR cells at one month.","groupId":"OG001","value":"NA"},{"comment":"There were no responders in this group so that means they did not have a mean percentage of E6 TCR cells at one month.","groupId":"OG002","value":"NA"},{"groupId":"OG003","lowerLimit":"30.1","upperLimit":"45.9","value":"38"},{"comment":"There were no responders in this group so that means they did not have a mean percentage of E6 TCR cells at one month.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Responders"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.7","upperLimit":"30.7","value":"30.7"},{"groupId":"OG001","lowerLimit":"4.4","upperLimit":"4.4","value":"4.4"},{"groupId":"OG002","lowerLimit":"12.6","upperLimit":"12.6","value":"12.6"},{"groupId":"OG003","lowerLimit":"10.4","upperLimit":"44.4","value":"29.9"},{"groupId":"OG004","lowerLimit":"21.7","upperLimit":"52.5","value":"37.1"}]}],"title":"Non-responders"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"Detection of E6 TCR T cells in patients peripheral blood leukocytes (PBL)/apheresis samples by flow cytometry.","dispersionType":"95% Confidence Interval","groups":[{"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"OG000","title":"HPV-16 E6 mTCR PBL 1x10^9 + HD IL-2"},{"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"OG001","title":"HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2"},{"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"OG002","title":"HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2"},{"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"OG003","title":"HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2"},{"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"OG004","title":"HPV-16 E6 mTCR PBL MTD + HD IL-2"}],"paramType":"MEAN","populationDescription":"One patient in group HPV-16 E6 mTCR PBL 1x10\\^10 + HD IL-2 did not have research blood collected at one month post infusion, and thus could not examine the cells for that patient at that time point.","reportingStatus":"POSTED","timeFrame":"One month after treatment","title":"Percentage of Cluster of Differentiation 3 (CD3+) Cells That Are E6 T-Cell Receptor Memory of Circulating T-Cells in Responders and Non-responders","type":"SECONDARY","unitOfMeasure":"percentage of cells"}